Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications
The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most patients with early-stage PCa can be treated with appropriate therapy, such as radical prostatectomy or irradiation. On the other hand, androgen deprivation therapy (ADT) is the standard systemic therapy...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2020 |
Language: | English |
Physical Description: | 1 electronic resource (184 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545855904498 |
---|---|
ctrlnum |
(CKB)5400000000040879 (oapen)https://directory.doabooks.org/handle/20.500.12854/68688 (EXLCZ)995400000000040879 |
collection |
bib_alma |
record_format |
marc |
spelling |
Ishii, Kenichiro edt Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020 1 electronic resource (184 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most patients with early-stage PCa can be treated with appropriate therapy, such as radical prostatectomy or irradiation. On the other hand, androgen deprivation therapy (ADT) is the standard systemic therapy given to patients with advanced PCa. ADT induces temporary remission, but the majority of patients (approximately 60%) eventually progress to castration-resistant prostate cancer (CRPC), which is associated with a high mortality rate. Generally, well-differentiated PCa cells are androgen dependent, i.e., androgen receptor (AR) signalling regulates cell cycle and differentiation. The loss of AR signalling after ADT triggers androgen-independent outgrowth, generating poorly differentiated, uncontrollable PCa cells. Once PCa cells lose their sensitivity to ADT, effective therapies are limited. In the last few years, however, several new options for the treatment of CRPC have been approved, e.g., the CYP17 inhibitor, the AR antagonist, and the taxane. Despite this progress in the development of new drugs, there is a high medical need for optimizing the sequence and combination of approved drugs. Thus, the identification of predictive biomarkers may help in the context of personalized medicine to guide treatment decisions, improve clinical outcomes, and prevent unnecessary side effects. In this Special Issue Book, we focused on the cytobiology of human PCa cells and its clinical applications to develop a major step towards personalized medicine matched to the individual needs of patients with early-stage and advanced PCa and CRPC. We hope that this Special Issue Book attracts the attention of readers with expertise and interest in the cytobiology of PCa cells. English Medicine bicssc androgen receptor docetaxel cabazitaxel castration-resistant prostate cancer chemotherapy P-glycoprotein EPI-002 splice variant prostate-specific antigen androgen deprivation therapy time to PSA nadir fibroblasts prostate cancer androgen sensitivity pirfenidone TGFβ1 G1 cell cycle arrest fibroblast growth factor fibroblast growth factor receptor obesity inflammation immune cells cytokine high-fat diet KIFC1 docetaxel resistance apoptosis CW069 Caveolin-1 TP53-regulated inhibitor of apoptosis 1 tumour stroma tumour microenvironment fibroblast CAF resistance radiotherapy CCL2 CCL22 CCL5 migration LSD1 epigenetics autophagy abiraterone enzalutamide testosterone castration resistant prostate cancer animal model diet fat in vitro in vivo mouse AKR1C3 hormone-naïve prostate cancer immunohistochemistry tissue microarray androgen receptor dependency fibroblast-dependent androgen receptor activation 3-03936-034-5 3-03936-035-3 Ishii, Kenichiro oth |
language |
English |
format |
eBook |
author2 |
Ishii, Kenichiro |
author_facet |
Ishii, Kenichiro |
author2_variant |
k i ki |
author2_role |
Sonstige |
title |
Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
spellingShingle |
Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
title_full |
Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
title_fullStr |
Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
title_full_unstemmed |
Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
title_auth |
Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
title_new |
Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
title_sort |
cytobiology of human prostate cancer cells and its clinical applications |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2020 |
physical |
1 electronic resource (184 p.) |
isbn |
3-03936-034-5 3-03936-035-3 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT ishiikenichiro cytobiologyofhumanprostatecancercellsanditsclinicalapplications |
status_str |
n |
ids_txt_mv |
(CKB)5400000000040879 (oapen)https://directory.doabooks.org/handle/20.500.12854/68688 (EXLCZ)995400000000040879 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796648786775244800 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04564nam-a2200997z--4500</leader><controlfield tag="001">993545855904498</controlfield><controlfield tag="005">20231214133528.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202105s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000040879</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/68688</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000040879</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ishii, Kenichiro</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (184 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most patients with early-stage PCa can be treated with appropriate therapy, such as radical prostatectomy or irradiation. On the other hand, androgen deprivation therapy (ADT) is the standard systemic therapy given to patients with advanced PCa. ADT induces temporary remission, but the majority of patients (approximately 60%) eventually progress to castration-resistant prostate cancer (CRPC), which is associated with a high mortality rate. Generally, well-differentiated PCa cells are androgen dependent, i.e., androgen receptor (AR) signalling regulates cell cycle and differentiation. The loss of AR signalling after ADT triggers androgen-independent outgrowth, generating poorly differentiated, uncontrollable PCa cells. Once PCa cells lose their sensitivity to ADT, effective therapies are limited. In the last few years, however, several new options for the treatment of CRPC have been approved, e.g., the CYP17 inhibitor, the AR antagonist, and the taxane. Despite this progress in the development of new drugs, there is a high medical need for optimizing the sequence and combination of approved drugs. Thus, the identification of predictive biomarkers may help in the context of personalized medicine to guide treatment decisions, improve clinical outcomes, and prevent unnecessary side effects. In this Special Issue Book, we focused on the cytobiology of human PCa cells and its clinical applications to develop a major step towards personalized medicine matched to the individual needs of patients with early-stage and advanced PCa and CRPC. We hope that this Special Issue Book attracts the attention of readers with expertise and interest in the cytobiology of PCa cells.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgen receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">docetaxel</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cabazitaxel</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">castration-resistant prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">P-glycoprotein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EPI-002</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">splice variant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate-specific antigen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgen deprivation therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">time to PSA nadir</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fibroblasts</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgen sensitivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pirfenidone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TGFβ1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">G1 cell cycle arrest</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fibroblast growth factor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fibroblast growth factor receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">obesity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytokine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">high-fat diet</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">KIFC1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">docetaxel resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">apoptosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CW069</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Caveolin-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TP53-regulated inhibitor of apoptosis 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumour stroma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumour microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fibroblast</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CCL2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CCL22</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CCL5</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">migration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LSD1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epigenetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autophagy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">abiraterone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">enzalutamide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">testosterone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">castration resistant prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">animal model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diet</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fat</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vitro</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vivo</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mouse</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">AKR1C3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hormone-naïve prostate cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tissue microarray</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">androgen receptor dependency</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fibroblast-dependent androgen receptor activation</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-034-5</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03936-035-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ishii, Kenichiro</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:56:52 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338069290004498&Force_direct=true</subfield><subfield code="Z">5338069290004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338069290004498</subfield></datafield></record></collection> |